303153-12-0

Upstream product

• 4025-77-8 chlorosulfonylacetyl chloride 
• 67-63-0 isopropyl alcohol 
• 56146-83-9 chlorosulfonyl-acetic acid methyl ester 

Downstream Products

• 1492047-44-5 2-{[(isopropoxy-2-oxoethyl)sulfonyl]amino}benzoic acid methyl ester 
• 771584-89-5 isopropyl ({[(2E)-3-(3-cyanophenyl)prop-2-en-1-yl][4-(4-methyl-1,4-diazepan-1-yl)phenyl]amino}sulfonyl)acetate 
• 946126-93-8 C₂₃H₁₈FN₃O₇S 
• 303153-22-2 2-biphenyl-4-ylmethyl-1,1-dioxo-2,3,6,7-tetrahydro-1H-1λ⁶-[1,2]thiazepine-7-carboxylic acid isopropyl ester 
• 303153-20-0 2-(4-bromo-benzyl)-1,1-dioxo-2,3,6,7-tetrahydro-1H-1λ⁶-[1,2]thiazepine-7-carboxylic acid isopropyl ester 

Relevant academic research and scientific papers

p27 PROTEIN INDUCER

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G 1 , G 2 , G 3 and G 8 are each independently selected from -N= etc., Ring G 6 is selected from divalent aryl etc., A is selected from amino etc., G 4 is selected from oxygen etc., G 5 is selected from oxygen etc., G 7 is selected from -CH 2 - etc., and R 2 is selected from C 1-6 alkyl etc.

2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa

The invention relates to 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of coagulation factor Xa. The compounds are suitable for the treatment and prophylaxis of cardiovascular and thrombotic events.

NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY

The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from -N= etc., Y3 and Y4 are selected from -CH= etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3

Highly potent and selective substrate analogue factor Xa inhibitors were obtained by incorporation of non-basic or modestly basic P1 residues known from the development of thrombin inhibitors. The modification of the P2 and P3 amino acids strongly influenced the selectivity and provided potent dual factor Xa and thrombin inhibitors without affecting the fibrinolytic enzymes. Several inhibitors demonstrated excellent anticoagulant efficacy in standard clotting assays in human plasma.

Ring-closing metathesis to a divergent endocyclic sulfonamide template

The efficient synthesis of a novel endocyclic sulfonamide template via a ring-closing metathesis methodology is reported. A solid-supported variant of the Grubbs catalyst is shown to be effective and the suitability of the template for both combinatorial derivatization and potential incorporation into peptidomimetics is demonstrated. (C) 2000 Published by Elsevier Science Ltd.

2′,3′-Cyclopropanated Nucleoside Dimers

Syntheses of three novel conformationally rigid dimers containing cyclopropyl -amide and -sulfonamide functionalities are described. Their incorporation into an oligonucleotide sequence resulted in considerable lowering of the Tm's in binding to their complementary RNA sequences.